1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Yuhan Corporation

Yuhan Corporation

70,300.00
KRW
+300.00
(+0.43%)
Nov 03Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
943,609
1,017,492
1,128,731
1,320,797
1,462,248
1,518,823
1,480,354
1,619,865
1,687,810
1,775,847
1,858,984
2,067,791
2,186,638
2,282,318
Operating Margin (%)
6.55
7.31
7.6
7.4
6.07
3.3
0.85
5.2
2.88
2.03
3.07
2.65
4.77
5.42
Depreciation Expense
18,903
26,513
31,056
42,920
52,195
59,000
58,658
59,785
52,671
43,019
44,410
63,041
69,156
77,708
Net Income, GAAP
86,461
90,948
126,047
161,249
109,034
57,481
40,006
192,761
102,583
95,144
136,198
70,687
194,079
237,086
Effective Tax Rate (%)
19.29
21.66
25.13
21.3
24.35
34.74
33.33
20.63
21.37
4.57
0.42
10.2
16.78
18.48
Profit Margin (%)
9.16
8.94
11.17
12.21
7.46
3.78
2.7
11.9
6.08
5.36
7.33
3.42
8.88
10.39
Working Capital
491,239
586,119
602,752
723,907
793,199
761,249
764,724
813,342
792,118
754,743
673,267
741,125
778,077
903,523
LT Debt
18,500
24,100
86,000
140,250
115,339
70,212
49,656
51,029
32,622
3,402
62,390
122,361
72,357
88,917
Total Equity
1,228,246
1,275,865
1,363,940
1,496,552
1,606,325
1,651,736
1,649,991
1,846,502
1,935,889
2,007,806
2,100,656
2,150,670
2,362,284
2,470,993
Return on Invested Capital (%)
4
4.41
4.45
4.75
3.87
1.84
0.47
3.58
1.87
1.63
2.57
2.07
3.36
3.74
Return on Capital (%)
7.03
7.05
8.97
10.31
6.52
3.36
2.59
10.63
5.38
4.95
6.56
4.19
8.37
9.83
Return on Common Equity (%)
7.16
7.27
9.56
11.28
7.05
3.55
2.44
11.07
5.45
4.87
6.75
3.41
8.81
10.45

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
267,318
263,708
260,614
LT Borrowings
71,117
91,117
88,917
LT Finance Leases
1,241
- -
- -
Preferred Equity and Hybrid Capital
1,181
1,181
1,181
Shares Outstanding
- -
- -
- -
Market Capitalization
- -
- -
- -

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,511,630
1,601,282
1,616,324
Cash, Cash Equivalents & STI
378,081
411,035
449,248
Accounts Receivable, Net
694,442
639,913
680,951
Inventories
372,764
437,746
419,982
Total Current Liabilities
733,553
788,489
712,801
Payables & Accruals
- -
- -
- -
ST Debt
267,318
263,708
260,614
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.71%
5.08%
9.84%
Free Cash Flow
-284.93%
-295.99%
-51.45%
Net Income, GAAP
41.53%
23.12%
174.56%
Sales/Revenue/Turnover
6.96%
6.21%
5.75%
Total Cash Common Dividend
7.73%
9.7%
16.6%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
444,593
528,312
598,785
496,101
2,067,791
2025
491,564
578,987
570,014
546,073
2,186,638
2026
526,780
639,452
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Wuk-Jae Cho
Full Time Employees
2,153
Sector
Health technology
Industry
Pharmaceuticals: major
Address
74, Noryangjin-ro Seoul SL South Korea 06927
IPO Date
Nov 1, 1962
Website
yuhan.co.kr
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Yuhan Corporation (000100.KS) manufactures and markets pharmaceuticals, health functional foods, and animal health products in South Korea. The company offers prescription drugs including analgesics, anti-inflammatories, and treatments for gastrointestinal disorders, metabolic diseases, and circulatory conditions; over-the-counter medications such as vitamins, cold remedies, and digestive aids; health functional foods under brands like Lacto; and animal health products including vaccines and feed additives. Yuhan operates primarily in the domestic Korean market with research and development facilities supporting its pharmaceutical pipeline, and it maintains international partnerships for technology transfers. Founded in 1926 and headquartered in Seoul, South Korea, the company recently expanded its animal health division through strategic investments and launched new formulations in its consumer health portfolio amid growing demand for functional foods.